Q-omics provides the consensus-scored MIR194-2HG profile across patient tissues and cancer cell-line models. MIR194-2HG expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in UCS. Among the 18 cancer types available for tumor–normal comparison, MIR194-2HG is differentially expressed in 11, with the highest sampling consensus in LIHC. Additionally, MIR194-2HG RNA expression shows 12,325 significant gene co-expression associations, with the highest sampling consensus in ESCA. Together, these results highlight UCS, LIHC, and ESCA as cancer lineages where MIR194-2HG shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR194-2HG — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR194-2HG survival associations across molecular data types. MIR194-2HG RNA expression shows survival associations in the most cancer types (22). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR194-2HG RNA expression–survival associations across cancer types. High MIR194-2HG expression shows unfavorable associations in ACC, LGG, PRAD and ESCA, but favorable associations in UCS and KIRC. The UCS Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCS as the clearest survival context for MIR194-2HG RNA expression.
This table summarizes MIR194-2HG tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in LIHC for RNA.
This table ranks reproducible tumor–normal expression differences for MIR194-2HG. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR194-2HG shows lower tumor expression in KICH, KIRP and THCA and higher tumor expression in LIHC, STAD and HNSC. The LIHC box plot shows higher MIR194-2HG RNA expression in tumor versus normal tissue (log2 FC = +0.491, t-test p < 0.001).
This table shows molecular features associated with MIR194-2HG in patient tissues and cancer cell lines. In patient samples, MIR194-2HG shows the broadest associations at the RNA and protein expression levels, with ESCA recurring as the lineage with the largest associated feature set.
